Version 1.15 release notes
Release notes
Changes to the NVC have been made since the last release v1.14 (2024-07-05). For your reference, please find a summary of the changes below:
The vaccine lot data that the NVC receives from Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (HC-BRDD) underwent a QA review, leading us to reconcile some discrepancies. Please contact NVC-CNV@phac-aspc.gc.ca if you would like a list of the specific lots updated. If you have already subscribed to receive updates (i.e., notifications of NVC releases by sending an email to NVC-CNV@phac-aspc.gc.ca), you will have received this information in your inbox as part of this week’s release. In summary of the specific changes: (1) The approval dates for 185 Sanofi Pasteur Limited vaccine lots were updated in the NVC to reflect the earliest approval date (refer to Excel tab 1 for specific lots). HC-BRDD is actively working on a solution to prevent this discrepancy from occurring in the future, though implementation of the fix may take some time. The NVC will continue collaborative periodic quality assurance checks with HC-BRDD and perform reconciliations as necessary until the issue is resolved. (2) HC-BRDD has recently updated the expiry dates for two vaccine lots in the NVC to reflect the correct original and current expiry dates (refer to Excel tab 2 for specific lots). (3) Additionally, HC-BRDD has documented shelf-life extensions for seven vaccine lots, updating their current expiry dates in the NVC accordingly (refer to Excel tab 3 for specific lots). (4) HC-BRDD has also recently edited the DIN associated with one lot number (refer to Excel tab 4 for the specific lot).
Summary of changes
- Antigen / Immunoglobulin / Antitoxin: 1
- Generic immunizing agent: 1
- Tradename immunizing agent: 2
- Vaccine lot: 200
- Version:
- 1.0.12